Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th


Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman Sachs Global Healthcare Conference on June 11, 2019 at 2:40 p.m. PT/5:40 p.m. ET at the Terranea Resort in Rancho Palos Verdes, Calif.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.magentatx.com. A replay of the webcast will be archived on the Magenta website for 60 days following each presentation.

About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statement
This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other risks set forth under the caption "Risk Factors" in Magenta's Registration Statement on Form S-1, as updated by Magenta's most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


These press releases may also interest you

at 08:05
Overplay, the first frictionless platform for user-generated games, announced today that Mark Cuban, renowned entrepreneur and "Shark" investor, has invested in the company after their appearance on ABC's Shark Tank which aired to over 4 million...

at 08:05
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed...

at 08:05
Resultant, a modern consulting firm specializing in data analytics, technology and digital transformation, announced that it has hired Nathan A. Ulery to serve as executive vice president of managed services. In this role, Ulery will serve on the...

at 08:05
Sprinklr , the unified customer experience management (Unified-CXM) platform for modern enterprises, announced the appointment of Amitabh Misra as Chief Technology Officer (CTO), effective April 1, 2024. Misra will lead all R&D teams across the globe...

at 08:05
CSC®, the world's leading provider of global business administration and compliance solutions, has been named SPV Administrator of the Year at the GlobalCapital European Securitization 2024 awards. The GlobalCapital European Securitization awards...

at 08:05
Iveda® , the global solution for cloud-based AI, today released new data which shows that 84% of Americans are concerned about the rising rate of violence in the United States. In fact, the average American (79%) noted that they have changed their...



News published on and distributed by: